Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

IL-33, sST2 y PCR en el Trastorno de Pánico

14 de noviembre de 2026 actualizado por: Mehmet Hamdi ÖRÜM, Elazığ Mental Health and Diseases Hospital

Investigación de IL-33, sST2 y Proteína C Reactiva en el Trastorno de Pánico: Un Estudio Transversal de Casos y Controles

Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

This is an observational, cross-sectional, case-control study conducted at the psychiatry outpatient clinic of Elazığ Mental Health and Diseases Hospital. It was planned to include 41 participants in the panic disorder (PD) and 30 healthy controls (HCs) groups. All participants will complete a sociodemographic data form and the DSM-5 Panic Disorder Severity Scale (Adult Form). Venous blood samples will be collected as 5 mL. Serum interleukin-33 (IL-33), soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels will be measured using commercially available ELISA kits. Statistical analyses will include independent samples t-test or Mann-Whitney U test, chi-square test, correlation, regression, and ROC analysis. A p value < 0.05 will be considered statistically significant.

Tipo de estudio

De observación

Inscripción (Actual)

71

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Elâzığ
      • Elâzığ, Elâzığ, Turquía (Türkiye), 23200
        • Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study population consisted of adult participants aged 18-65 years. The panic disorder (PD) group included consecutive subjects diagnosed with PD according to DSM-5-TR criteria who were admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. All participants provided informed consent prior to enrollment.

Descripción

  1. For Panic Disorder (PD) Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
    • Not having previously used any medication for psychiatric purposes (drug-naive)
    • Not having any additional active psychiatric disorders besides PD at the current presentation
    • Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Not having taken any medication or supplements in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For PD Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range

    • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health

    • Having a history of psychiatric medication use

    • Having an additional psychiatric disorder besides PD at the current application

    • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study
  2. For Healthy Control Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Not having any active psychiatric disorder

    • Not having previously used any medication for psychiatric purposes (drug-naive)

    • Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer

    • Not having taken any medication or supplement in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For Healthy Control Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range
    • Having any active psychiatric disorder
    • Having a history of using psychiatric medication
    • Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: CROSS_SECTIONAL

Cohortes e Intervenciones

Grupo / Cohorte
Panic Disorder (PD)

Adult participants (18-65 years) diagnosed with panic disorder (PD) according to DSM-5-TR criteria. All of the subjects with PD was drug-naive. Subjects were evaluated at baseline. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters. Clinical assessments in the PD group included the DSM-5 Panic Disorder Severity Scale (Adult Form). Sociodemographic and clinical data were recorded for all participants.

Healthy Control (HC)

Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Interleukin-33 (IL-33)
Periodo de tiempo: At hospital admission (baseline)

Interleukin-33 (IL-33) levels measured by ELISA (pg/ml).

At hospital admission (baseline)
Soluble Suppressor Tumorogenicity-2 (sST2)
Periodo de tiempo: At hospital admission (baseline)

Soluble Suppressor Tumorogenicity-2 (sST2) levels measured by ELISA (pg/ml)

At hospital admission (baseline)
C-Reactive Protein (CRP)
Periodo de tiempo: At hospital admission (baseline)

C-Reactive Protein (CRP) levels measured by ELISA (mg/dL)

At hospital admission (baseline)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Systemic Inflammation Response Index (SIRI)
Periodo de tiempo: At hospital admission (baseline)

SIRI was calculated as (neutrophil count × monocyte count)/lymphocyte count. Laboratory staff were blinded to group status.

At hospital admission (baseline)
DSM-5 Panic Disorder Severity Scale-Adult Form (PDS)
Periodo de tiempo: At hospital admission (baseline)

The DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) is a 10-item self-assessment scale developed by the American Psychiatric Association (APA) that uses a five-point Likert scale (0=Never; 1=Sometimes; 2=Halfway through; 3=Most of the time; 4=Always). Participants consider how much their panic disorder has affected their personal lives in the past seven days when completing the scale. Scores obtained from the scale items indicate the severity of the panic disorder. The scale can be scored between 0 and 40, with higher scores indicating a more severe panic disorder. The mean total score is calculated by dividing the total raw score by the number of items on the scale.

At hospital admission (baseline)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de julio de 2025

Finalización primaria (Actual)

5 de marzo de 2026

Finalización del estudio (Actual)

5 de marzo de 2026

Fechas de registro del estudio

Enviado por primera vez

25 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

25 de febrero de 2026

Publicado por primera vez (Actual)

3 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • EMHDH-2025-2026-PD-IL33-ST2-CR

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Deidentified individual participant data (IPD) underlying the results reported in this study (including demographic variables, serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2) and C-reactive protein (CRP) levels, complete blood count parameters, and DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) will be made available to qualified researchers upon reasonable request for academic purposes. Data will be shared after removal of all direct identifiers and in accordance with applicable ethical approvals and data protection regulations. Access to the data will require a methodologically sound research proposal and a data use agreement. Requests should be directed to the corresponding author.

Marco de tiempo para compartir IPD

Data will be available beginning 6 months after publication and will remain available for 5 years.

Criterios de acceso compartido de IPD

Access will be granted to researchers who provide a methodologically sound proposal. Requests must be approved by the principal investigator and may require a data use agreement in accordance with institutional and ethical regulations.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir